Covalon Technologies (COV) Q2 2025 earnings summary

Executive summary

• Achieved fifth consecutive quarter of positive adjusted EBITDA and profitability, with year-to-date revenue up 21% to $15.8M and trailing twelve months revenue at $33.8M, up 29%.

• Cash on hand increased to over $18 million as of March 31, 2025, with no debt, up $10.8 million from the prior year.

• Strong customer retention and new hospital acquisitions, including 100% retention of top 50 U.S. hospital customers and 50 new accounts added in the first half.

• Strategic focus on market development, clinical evidence generation, expanding partnerships, and M&A to accelerate adoption and growth.

• No material impact from tariffs due to North American-centric manufacturing, providing a competitive advantage.

Financial highlights

• Q2 FY'25 revenue was $7.5M–$7.6M, down sequentially but up 20.5% year-over-year, with gross margin at 54.6%–55%.

• Year-to-date revenue reached $15.8M, up from $13.1M in the prior year.

• Gross margin for Q2 was 55%, and year-to-date gross margin was 58%.

• Adjusted EBITDA for Q2 YTD FY'25 increased 57.2% to $2.1M, with trailing twelve months at $5.6M.

• EPS for Q2 YTD FY'25 improved to $0.06 from $0.02 year-over-year.

Outlook and guidance

• Sequential quarterly growth anticipated in Q3 and a stronger second half, with clear visibility from in-house orders and partner trends.

• Gross margins expected to rebound as U.S. sales channel growth resumes.

• No formal quarterly guidance issued due to current stage and revenue predictability.

• Positioned for strong multi-year growth, with focus on commercial advancement, market development, and innovation.